Dublin – 3 Nov. 2023 – Zoetis Inc., the world's leading animal health company, today marked One Health Day with an exclusive tour of its expanding state-of-the-art manufacturing facility in Tullamore, Co. Offaly. One Health Day brings attention to and celebrates the interconnection between people, animals and their shared environment, an approach Zoetis is committed to, and which is mirrored in its innovative portfolio of animal health solutions.
The event is on the heels of the recent completion of the construction phase of the significant Tullamore Expansion Project, which has created 80-100 new jobs. This new facility for the production of so-called biologicals, will see a further fourfold expansion to Tullamore manufacturing capacity. The Tullamore team has grown to 180 colleagues since the site’s acquisition in 2017. There will be further future employment when the site reaches maximum capacity in 2025.
Zoetis has been manufacturing animal health products in Ireland since the purchase of its Tallaght site in 1975. The Tullamore expansion builds on the company’s current footprint in Ireland, which includes commercial offices and manufacturing sites, employing more than 500 people. Zoetis’ Cherrywood Dublin office is the headquarters for its International Commercial Operations and Global Manufacturing and Supply organizations, as well as the home of local commercial operations for Ireland. In addition to Tullamore, Zoetis has two manufacturing sites in Ireland that play critical roles in its manufacturing network. The manufacturing site in Rathdrum, Co. Wicklow supports many Zoetis flagship products, and products from the Tallaght facility are exported to over 80 markets around the world.
The recent investment in Tullamore will significantly increase the company’s capacity to produce veterinary monoclonal antibodies (mAbs), which are therapeutic biopharmaceuticals and one of the latest breakthroughs in animal health.
In attendance at the site visit was Minister for State at the Department of Agriculture, Food and the Marine, Pippa Hackett, who was welcomed to Zoetis Tullamore by Site Lead Conor O’Dea.
Minister of State for the Department of Agriculture, Food and the Marine Pippa Hackett said: “I wish to extend my thanks to the entire team in Tullamore for the warm welcome and the opportunity to witness first-hand the cutting-edge work being done here. The recent investments in Tullamore emphasise the strategic importance of Ireland in Zoetis’ global operations and I wish Zoetis continued success and growth for the years ahead.”
Zoetis Tullamore Site Lead Conor O’Dea said: “This site visit was a great opportunity not only to showcase our expanding production facilities, but also to explain how our range of monoclonal antibodies helps alleviate osteoarthritis pain in dogs and cats, or target and neutralize itch for dogs with allergic or atopic dermatitis.”
Jamie Brannan, Executive Vice President and Group President, International Operations, Aquaculture and Global Diagnostics, said: “As a purpose-driven company working to create a healthier planet for animals and people, our team was delighted to welcome Minister Hackett on One Health Day to highlight the importance of this approach in the animal health industry. The concept of “One Health” is essential to Zoetis and we are committed to developing sustainable animal health solutions that support animals, people and the planet. The Tullamore site will help to advance our commitment to One Health. The innovative monoclonal antibodies produced here will positively impact animals not only in Ireland, but in many countries around the world where we market our products.”
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; the impact of the coronavirus (COVID-19) global pandemic and any recovery therefrom on our business, supply chain, customers and employees; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; tax rates and tax regimes and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Media Contacts:
Laura Panza
+1-973-975-5176
laura.panza@zoetis.com
Nantaara Jafri
+49-160-95655301
nantaara.jafri@zoetis.com